Avalon GloboCare's Strategic Moves: Merger with YOOV and DKAir™ Collaboration Boost Investor Confidence
By ATTN Desk · Editorial oversight: Sean Han
Introduction
AVALON GLOBOCARE CORP (NASDAQ: ALBT) is a commercial-stage company focused on developing and delivering precision diagnostics and clinical laboratory services. The company’s offerings include general bloodwork, anatomic pathology, urine toxicology, and pharmacogenomics (PGx) testing. Avalon also markets the KetoAir™ breathalyzer device, registered with the U.S. Food and Drug Administration as a Class I medical device, and owns commercial real estate assets.
Corporate Structure
Avalon GloboCare is listed on NASDAQ under ticker ALBT, with approximately 2.95 million shares outstanding. The executive leadership team includes:
• Dr. David Jin, MD, PhD – Chief Executive Officer, President, and Director; previously Chief Medical Officer of BioTime, Inc.; senior translational clinician-scientist at Howard Hughes Medical Institute and Weill Cornell Medicine.
• Meng Li – Chief Marketing Officer and Corporate Secretary, with over 15 years in international marketing, branding, and media consultancy.
• Luisa Ingargiola – Chief Financial Officer, with experience as CFO and Audit Chair at multiple NASDAQ- and NYSE-listed companies, including ElectraMeccanica and Dragonfly Energy.
The specific headcount of Avalon’s workforce is not disclosed, but it comprises clinical scientists, laboratory specialists, and business professionals with relevant degrees and industry experience.
Breathalyzer by H&CO
Developments and News
On April 29, 2025, Avalon filed a Registration Statement on Form S-4 with the U.S. Securities and Exchange Commission in connection with a proposed merger with YOOV Group Holding Limited. Under the Merger Agreement dated March 7, 2025, YOOV, a provider of AI-based automation solutions, will become a wholly owned subsidiary of Avalon, subject to stockholder approval and Nasdaq listing consent.
On July 22, 2025, Avalon announced a collaboration with Qi Diagnostics to co-develop the DKAir™ breathalyzer for early detection of diabetic ketoacidosis (DKA). The multi-center clinical study aims to evaluate non-invasive monitoring in patients with type 1 diabetes.
In July 2025, Avalon filed three Current Reports on Form 8-K (July 18, July 23, and July 28), covering items related to corporate developments and executive updates.
Financial and Strategic Analysis
Avalon’s share price increased on July 28, 2025, following the merger filing and clinical partnership announcement. Key financial and trading metrics as of July 28, 2025, are shown below:
| Metric | Value |
|---|---|
| Closing Price | $4.00 |
| Daily Change | +76.21 % |
| Volume | 5,470,114 |
| Market Capitalization | $12.11 million |
| 52-Week Range | $2.11 – $12.60 |
| Revenue (TTM) | $1.369 million |
| Net Margin (TTM) | –658.91 % |
| Debt to Equity (MRQ) | 209.26 % |
| 10-Day Average Volume | 1.24 million |
Avalon is currently unprofitable based on Generally Accepted Accounting Principles, reflecting ongoing investments in diagnostics R&D and infrastructure. The proposed merger with YOOV is expected to diversify revenue through AI-as-a-Service offerings, while the DKAir™ device could potentially add a new clinical product line. Achieving regulatory clearance, clinical validation, and successful integration of AI capabilities are central to Avalon’s strategy.
Market Position and Industry Context
Avalon operates within the global precision diagnostics and clinical laboratory services sector, which is influenced by demand for personalized medicine and rapid, point-of-care testing. Its comprehensive service model competes with larger diagnostic networks by integrating a broad test menu with evolving digital health technologies. The incorporation of AI-driven workflow automation through the proposed merger with YOOV aligns Avalon with industry trends focused on improving operational efficiency in healthcare delivery.
TL;DR
On April 29, 2025, Avalon filed an S-4 for a merger with AI automation provider YOOV Group, pending shareholder and Nasdaq approvals. On July 22, 2025, the company entered a co-development agreement with Qi Diagnostics to validate the DKAir™ breathalyzer for monitoring diabetic ketoacidosis. Shares increased by 76.21 % to $4.00 on July 28, 2025. The merger is anticipated to enhance AI-as-a-Service capabilities, and the outcomes of the DKAir™ study will inform the device’s commercial prospects. Investors should monitor the SEC’s declarations regarding the proxy statement and results from clinical trials for DKAir™.